✦ LIBER ✦

PACE: A Pivotal Phase 2 Trial of Ponatinib in Patients With CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or With the T315I Mutation

✍ Scribed by Cortes, Jorge E.; Kim, Dong-Wook; Pinilla, Javier; Paquette, Ronald; le Coutre, Philipp D.; Chuah, Charles; Nicolini, Franck E.; Apperley, Jane F.; Jean Khoury, H.; Talpaz, Moshe; DiPersio, John F.; DeAngelo, Daniel J; Rea, Delphine; Abruzzese, Elisabetta; Mueller, Martin C.; Baccarani, Michele; Gambacorti-Passerini, Carlo; Turner, Christopher D.; Haluska, Frank; Kantarjian, Hagop M.

Book ID: 123543341
Publisher: Elsevier
Year: 2013
Tongue: English
Weight: 65 KB
Volume: 13
Category: Article
ISSN: 2152-2650
DOI: 10.1016/j.clml.2013.07.098

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase I/II study of nilotinib in Japan

A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL

✍ Arinobu Tojo; Kensuke Usuki; Akio Urabe; Yasuhiro Maeda; Yukio Kobayashi; Itsuro 📂 Article 📅 2009 🏛 Carden Jennings Publishing 🌐 English ⚖ 184 KB

Efficacy and safety of nilotinib in Japa

Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study

✍ Kensuke Usuki; Arinobu Tojo; Yasuhiro Maeda; Yukio Kobayashi; Akira Matsuda; Kaz 📂 Article 📅 2012 🏛 Carden Jennings Publishing 🌐 English ⚖ 285 KB

Cost-Consequence Analysis of a Treatment

Cost-Consequence Analysis of a Treatment Strategy Including Ponatinib Compared to a Treatment Strategy Including Only the 2nd Generation Tyrosine Kinase Inhibitors (2g TKIs), Dasatinib or Nilotinib, in Resistant Patients with Philadelphia Chromosome-Positive (Ph+) Leukemia, in Italy

✍ Chiroli, S.; Furneri, G.; Pane, F. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB